USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
INSIGHT GENETICS, INC.
Address:
111 10th Ave. South Suite 110
NASHVILLE, TN 37203-
Phone:
N/A
URL:
N/A
EIN:
120212289
DUNS:
190114962
Number of Employees:
20
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $399,576.00 2
SBIR Phase II $2,995,210.00 2

Award List:

Companion Diagnostic for ALK Mutations

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
David Hout
Abstract:
Kinase inhibitors such as Gleevec and Tarceva have markedly improved cancer therapy. Essential to the use of such inhibitors are companion diagnostics enabling determination of the mutational status of th eir kinase targets in tumors. Anaplastic lymphoma kinase (ALK) fusion oncogenes have emerged as… More

OTHER FUNCTIONS DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR ALK MUTATIONS.

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,495,220.00
Agency:
HHS
Principal Investigator:
David Hout – 615-255-8880
Abstract:
Constitutively activated forms of ALK caused by genetic aberrations have been shown to cause an expanding variety of human cancers. The FDA recently approved the Pfizer drug Xalkori (crizotinib) to treat patients with non-small cell lung cancers (NSCLC) that express ALK. Numerous other… More

IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$199,576.00
Agency:
HHS
Principal Investigator:
Dr. david Hout – 615-255-8880
Abstract:
Lung cancer is the main cause of cancer mortality worldwide with 80% non-small cell lung cancer (NSCLC) in type and mainly driven by three mutually exclusive oncogenes, EGFR, KRAS and ALK (collectively between 30-60% of all NSCLC cases). Oncogenic driverssuch as ROS1 and RET fusions and DEPDC1… More

TOPIC 277 PHASE II; COMPANION DIAG: PREDICTIVE AND PROGNOSTIC TEST ENABLING PERSO

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,499,990.00
Agency:
HHS
Principal Investigator:
David Hout – 615-255-8880
Abstract:
Not Available